Enteroendocrine Cells Before and After Sleeve Gastrectomy

University Hospital Basel

Status: Completed

Conditions: Obesity

Treatments: Procedure: sleeve gastrectomy; Other: no intervention

Study type: Interventional

Funder types: Other

Identifiers

NCT02589587

EEC

Details and patient eligibility

About

Morbidly obese patients exhibit impaired secretion of satiation hormones which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls.

Full description

Morbidly obese patients exhibit impaired secretion of satiation hormones cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. A better understanding of mechanisms involved will assist in development of non-invasive therapeutic strategies. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls. Gastric and intestinal mucosa will be collected by endoscopy from morbidly obese subjects before and 3 months after sleeve gastrectomy. In Addition, lean controls will be examined. Expression of various gut peptides will be assessed by immunohistochemistry and quantitative polymerase chain reaction (PCR).

Enrollment: 40 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Morbidly obese patients scheduled for sleeve gastrectomy

• BMI > 35 kg/m2
• Age: > 18-65 years Lean, healthy controls
• BMI > 18 and < 28kg/m2
• Age: >18-40 years

Exclusion criteria

• Bleeding diathesis
• Previous surgery on the gastrointestinal tract (appendectomy acceptable)

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

sleeve gastrectomy

Active Comparator group

Description:

Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.

Treatment:

Procedure: sleeve gastrectomy

no intervention

Other group

Description:

Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.

Treatment:

Other: no intervention